Gut Microbiota-Fermented Trisaccharide Shows Potential Against Campylobacter

In a study published in Marine Life Science & Technology, researchers explored the effects of a specific fucose-containing trisaccharide, GuFGa, on the common enteric pathogen Campylobacter jejuni. This research utilized both metabolomic and transcriptomic analyses to understand the interactions within a microbial community when GuFGa is fermented by human fecal microbiota.

Investigating the Role of GuFGa

Fucose-rich carbohydrates like 2'-fucosyllactose and fucoidan are known for their anti-infective properties. The study aimed to determine how GuFGa, a trisaccharide composed of β-D-Glc p-(1→4)-[β-D-Gal p-(1→3)]-α-ʟ-Fuc p, affects C. jejuni when fermented by gut microbiota. The researchers conducted in vitro experiments using a cell-based model to assess the protective effects of metabolites derived from GuFGa fermentation.

The study found that while GuFGa itself did not directly inhibit the growth of C. jejuni in single-strain cultures, the supernatant from GuFGa fermented with human fecal microbiota (F-GuFGa) significantly reduced the pathogen's relative abundance by tenfold within a complex microbial community. This suggests that the fermentation process and the resulting metabolites play a crucial role in inhibiting C. jejuni.

Metabolomic and Transcriptomic Insights

To further understand the mechanisms at play, the researchers examined changes in gene expression and metabolite abundance. Transcriptome analysis revealed 128 differentially expressed genes in C. jejuni after F-GuFGa treatment. These genes were primarily associated with oxidative phosphorylation and bacterial secretion systems, particularly type IV secretion systems.

Metabolomic analysis showed alterations in 452 metabolites, with notable changes in phenylalanine and tryptophan metabolism. A correlation analysis indicated a significant negative relationship between the expression of type IV secretion system genes and the abundance of phenylacetic acid (PAA) and D-3-phenyllactic acid (D-PLA). This suggests that these metabolites may interfere with the pathogen's ability to utilize its secretion systems effectively.

Potential Implications and Limitations

The study also explored the impact of F-GuFGa, PAA, and D-PLA on the adhesion of C. jejuni to Caco-2 cells, a model for intestinal epithelial cells. Results showed that F-GuFGa reduced adhesion by 44.4%, with D-PLA showing a 33.3% reduction. These findings highlight the potential of GuFGa-derived metabolites in inhibiting bacterial adhesion, a critical step in infection.

While these results are promising, it is important to acknowledge the study's limitations. The research was conducted in vitro, which may not fully replicate the complex interactions within the human gut. Additionally, the study's findings are preliminary and require further validation in animal models or human trials to confirm their applicability in real-world scenarios.

For those interested in the broader implications of microbiota and gut health, our post on the microbiota-gut-brain axis provides further insights into how gut microbiota can influence various physiological processes.